Patents by Inventor Stephen Holgate

Stephen Holgate has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9089535
    Abstract: The present invention provides the use of IFN-?, an agent that increases the expression of IFN-?, or a polynucleotide which is capable of expressing IFN-? or said agent for the manufacture of a medicament for the treatment of rhinovirus-induced exacerbation of a respiratory disease selected from asthma and chronic obstructive pulmonary disease, wherein said treatment is by airway delivery of said medicament, e.g. by use of an aerosol nebuliser. Also provided is IFN-? for the same purpose.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: July 28, 2015
    Assignee: Imperial Innovations Limited
    Inventors: Donna Elizabeth Davies, Peter Alexander Blanch Wark, Stephen Holgate, Sebastian L. Johnston
  • Publication number: 20130209399
    Abstract: The present invention provides the use of IFN-?, an agent that increases the expression of IFN-?, or a polynucleotide which is capable of expressing IFN-? or said agent for the manufacture of a medicament for the treatment of rhinovirus-induced exacerbation of a respiratory disease selected from asthma and chronic obstructive pulmonary disease, wherein said treatment is by airway delivery of said medicament, e.g. by use of an aerosol nebuliser. Also provided is IFN-? for the same purpose.
    Type: Application
    Filed: August 16, 2012
    Publication date: August 15, 2013
    Inventors: Donna Elizabeth DAVIES, Peter Alexander Blanch Wark, Stephen Holgate, Sebastian L. Johnston
  • Patent number: 8273342
    Abstract: The present invention provides the use of IFN-?, an agent that increases the expression of IFN-?, or a polynucleotide which is capable of expressing IFN-? or said agent for the manufacture of a medicament for the treatment of rhinovirus-induced exacerbation of a respiratory disease selected from asthma and chronic obstructive pulmonary disease, wherein said treatment is by airway delivery of said medicament, e.g. by use of an aerosol nebulizer. Also provided is IFN-? for the same purpose.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: September 25, 2012
    Assignee: University of Southampton
    Inventors: Donna Elizabeth Davies, Peter Alexander Blanch Wark, Stephen Holgate, Sebastian L. Johnston
  • Publication number: 20090257980
    Abstract: The present invention provides the use of IFN-?, an agent that increases the expression of IFN-?, or a polynucleotide which is capable of expressing IFN-? or said agent for the manufacture of a medicament for the treatment of rhinovirus-induced exacerbation of a respiratory disease selected from asthma and chronic obstructive pulmonary disease, wherein said treatment is by airway delivery of said medicament, e.g. by use of an aerosol nebuliser. Also provided is IFN-? for the same purpose.
    Type: Application
    Filed: June 18, 2009
    Publication date: October 15, 2009
    Inventors: Donna Elizabeth DAVIES, Peter Alexander Blanch Wark, Stephen Holgate, Sebastian L. Johnston
  • Patent number: 7569216
    Abstract: The present invention provides the use of IFN-?, an agent that increases the expression of IFN-?, or a polynucleotide which is capable of expressing IFN-? or said agent for the manufacture of a medicament for the treatment of rhinovirus-induced exacerbation of a respiratory disease selected from asthma and chronic obstructive pulmonary disease, wherein said treatment is by airway delivery of said medicament, e.g. by use of an aerosol nebuliser. Also provided is IFN-? for the same purpose.
    Type: Grant
    Filed: September 8, 2006
    Date of Patent: August 4, 2009
    Assignee: University of Southampton
    Inventors: Donna Elizabeth Davies, Peter Alexander Blanch Wark, Stephen Holgate, Sebastian L. Johnston
  • Publication number: 20080070838
    Abstract: The present invention relates to use of epidermal growth factor (EGF) analogues to treat, or protect from, bronchial epithelium damage in asthma patients. Suitable such analogues target the EGF receptor and exhibit ability to promote in asthma patients preferential proliferation of bronchial epithelial cells compared to airway fibroblasts.
    Type: Application
    Filed: September 13, 2005
    Publication date: March 20, 2008
    Applicant: University of Southampton
    Inventors: Donna Davies, Stephen Holgate, Lynnsey Hamilton, Sarah Puddicombe, Audrey Richter
  • Patent number: 7312047
    Abstract: The present invention relates to the use of an air-liquid interface culture model using asthmatic bronchial epithelial cells, which exhibit impaired epithelial barrier function. It is proposed to use asthmatic epithelial cultures, in the absence of added Th2 or proinflammatory cytokines such as IL-13, as an in vitro model to screen for agents that can act to improve impaired asthmatic epithelial barrier function. Such agents may have therapeutic utility in asthma patients.
    Type: Grant
    Filed: May 24, 2005
    Date of Patent: December 25, 2007
    Assignee: University of Southampton
    Inventors: Sarah M. Puddicombe, Donna Elizabeth Davies, Stephen Holgate
  • Publication number: 20070134763
    Abstract: The present invention provides the use of IFN-?, an agent that increases the expression of IFN-?, or a polynucleotide which is capable of expressing IFN-? or said agent for the manufacture of a medicament for the treatment of rhinovirus-induced exacerbation of a respiratory disease selected from asthma and chronic obstructive pulmonary disease, wherein said treatment is by airway delivery of said medicament, e.g. by use of an aerosol nebuliser. Also provided is IFN-? for the same purpose.
    Type: Application
    Filed: September 8, 2006
    Publication date: June 14, 2007
    Applicants: University of Southampton Highfield, Imperial Innovations Limited
    Inventors: Donna Davies, Peter Wark, Stephen Holgate, Sebastian Johnston
  • Publication number: 20060269909
    Abstract: The present invention relates to the use of an air-liquid interface culture model using asthmatic bronchial epithelial cells, which exhibit impaired epithelial barrier function. It is proposed to use asthmatic epithelial cultures, in the absence of added Th2 or proinflammatory cytokines such as IL-13, as an in vitro model to screen for agents that can act to improve impaired asthmatic epithelial barrier function. Such agents may have therapeutic utility in asthma patients.
    Type: Application
    Filed: May 24, 2005
    Publication date: November 30, 2006
    Inventors: Sarah Puddicombe, Donna Davies, Stephen Holgate